Hematologic and molecular responses to ropeginterferon alfa‐2b therapy of polycythemia vera: 48‐week results from a prospective study
Abstract To prevent thrombosis in patients with polycythemia vera (PV), achieving a complete hematologic response (CHR) is highly recommended in practice. In addition, a reduced JAK2 V617F mutation burden is expected to have a disease‐modifying effect, and its molecular response (MR) is currently of...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | 英语 |
| 出版: |
2025
|
| 在線閱讀: | https://doi.org/10.1002/ijc.35411 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|